Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Cakiroglu E., Şentürk Ş.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol.21, no.17, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 21 Issue: 17
  • Publication Date: 2020
  • Doi Number: 10.3390/ijms21176342
  • Journal Name: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED)
  • Keywords: malignant pleural mesothelioma, genomics, functional genomics, next-generation sequencing, RNAi and CRISPR screens, POTENTIAL THERAPEUTIC TARGETS, TUMOR-SUPPRESSOR, GROWTH-FACTOR, GENE-EXPRESSION, MOUSE MODEL, MESENCHYMAL TRANSITION, LUNG ADENOCARCINOMA, SOMATIC MUTATIONS, BAP1 ALTERATIONS, INHIBITS GROWTH
  • Dokuz Eylül University Affiliated: Yes

Abstract

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.